دورية أكاديمية
أعرض في EDS

Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation.

التفاصيل البيبلوغرافية
العنوان: Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation.
المؤلفون: Kanaan SB; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.; Research and Development, Chimerocyte Inc, Seattle, WA., Urselli F; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Radich JP; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Nelson JL; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.; Research and Development, Chimerocyte Inc, Seattle, WA.; Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA.
المصدر: Blood advances [Blood Adv] 2023 Oct 24; Vol. 7 (20), pp. 6066-6079.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Society of Hematology, [2016]-
مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation* , Leukemia, Myeloid, Acute*, Humans ; Transplantation, Homologous ; Chimerism ; Retrospective Studies ; Recurrence
مستخلص: Increasing mixed chimerism (reemerging recipient cells) after allogeneic hematopoietic cell transplant (allo-HCT) can indicate relapse, the leading factor determining mortality in blood malignancies. Most clinical chimerism tests have limited sensitivity and are primarily designed to monitor engraftment. We developed a panel of quantitative polymerase chain reaction assays using TaqMan chemistry capable of quantifying chimerism in the order of 1 in a million. At such analytic sensitivity, we hypothesized that it could inform on relapse risk. As a proof-of-concept, we applied our panel to a retrospective cohort of patients with acute leukemia who underwent allo-HCT with known outcomes. Recipient cells in bone marrow aspirates (BMAs) remained detectable in 97.8% of tested samples. Absolute recipient chimerism proportions and rates at which these proportions increased in BMAs in the first 540 days after allo-HCT were associated with relapse. Detectable measurable residual disease (MRD) via flow cytometry in BMAs after allo-HCT showed limited correlation with relapse. This correlation noticeably strengthened when combined with increased recipient chimerism in BMAs, demonstrating the ability of our ultrasensitive chimerism assay to augment MRD data. Our technology reveals an underappreciated usefulness of clinical chimerism. Used side by side with MRD assays, it promises to improve identification of patients with the highest risk of disease reoccurrence for a chance of early intervention.
(© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
References: Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19600-19608. (PMID: 31501349)
Blood. 2013 Sep 5;122(10):1813-21. (PMID: 23847197)
Biol Blood Marrow Transplant. 2014 Oct;20(10):1522-9. (PMID: 24907626)
Leukemia. 2001 Feb;15(2):293-302. (PMID: 11236950)
Haematologica. 2022 May 01;107(5):1045-1053. (PMID: 34382386)
Oncoimmunology. 2017 Mar 31;6(5):e1311436. (PMID: 28638735)
Bone Marrow Transplant. 1996 Dec;18(6):1161-5. (PMID: 8971389)
Nat Rev Immunol. 2017 Aug;17(8):483-494. (PMID: 28480895)
Leuk Lymphoma. 2016 Aug;57(8):1965-8. (PMID: 26726757)
J Clin Oncol. 2016 Feb 1;34(4):329-36. (PMID: 26668349)
Blood. 2008 Feb 15;111(4):1827-33. (PMID: 18048644)
Bone Marrow Transplant. 2007 Mar;39(5):285-91. (PMID: 17262061)
Bone Marrow Transplant. 2022 Mar;57(3):347-359. (PMID: 35082369)
Bone Marrow Transplant. 2021 May;56(5):1090-1098. (PMID: 33257776)
Ann Hematol. 2002;81 Suppl 2:S27-8. (PMID: 12611065)
Cell Mol Immunol. 2014 Nov;11(6):589-94. (PMID: 25242272)
Cytometry B Clin Cytom. 2016 Jan;90(1):47-53. (PMID: 25906832)
Leukemia. 2017 Jul;31(7):1482-1490. (PMID: 28386105)
N Engl J Med. 2018 Mar 29;378(13):1189-1199. (PMID: 29601269)
Acta Obstet Gynecol Scand. 2023 Jun;102(6):690-698. (PMID: 36933003)
Leukemia. 2012 Mar;26(3):381-9. (PMID: 21886171)
Blood. 2013 Feb 14;121(7):1077-82. (PMID: 23243288)
Blood Rev. 2017 Mar;31(2):63-75. (PMID: 27742133)
Leukemia. 2001 Dec;15(12):1976-85. (PMID: 11753621)
Biol Blood Marrow Transplant. 2016 Jul;22(7):1227-1233. (PMID: 27064057)
Arthritis Rheum. 2004 Mar;50(3):906-14. (PMID: 15022334)
Blood. 2014 Oct 30;124(18):2793-803. (PMID: 25237199)
Haematologica. 2009 Nov;94(11):1613-7. (PMID: 19880783)
Exp Hematol. 2010 Dec;38(12):1261-71. (PMID: 20851159)
Arthritis Rheum. 2011 Mar;63(3):640-4. (PMID: 21360493)
N Engl J Med. 1979 May 10;300(19):1068-73. (PMID: 34792)
Lab Invest. 2006 Nov;86(11):1185-92. (PMID: 16969370)
Br J Haematol. 2000 Mar;108(4):761-8. (PMID: 10792281)
Lancet Oncol. 2018 Dec;19(12):1668-1679. (PMID: 30442503)
Stat Med. 1998 Apr 30;17(8):857-72. (PMID: 9595616)
Haematologica. 2016 Jun;101(6):741-6. (PMID: 26869631)
Expert Opin Ther Targets. 2014 Jul;18(7):715-8. (PMID: 24750020)
Transplantation. 1987 Nov;44(5):643-50. (PMID: 3318034)
Bone Marrow Transplant. 1997 Apr;19(7):697-702. (PMID: 9156247)
JAMA Oncol. 2020 Dec 01;6(12):1890-1899. (PMID: 33030517)
Haematologica. 2003 Jul;88(7):801-10. (PMID: 12857560)
N Engl J Med. 2009 Nov 5;361(19):1872-85. (PMID: 19890130)
Blood. 2014 Nov 27;124(23):3345-55. (PMID: 25049280)
Bone Marrow Transplant. 2013 Aug;48(8):1070-6. (PMID: 23376821)
Bone Marrow Transplant. 2000 Apr;25(8):843-51. (PMID: 10808205)
Trends Immunol. 2012 Aug;33(8):421-7. (PMID: 22609148)
Bone Marrow Transplant. 2014 Oct;49(10):1269-77. (PMID: 25089597)
Blood. 2010 Nov 25;116(22):4693-9. (PMID: 20686119)
Methods Mol Biol. 2013;999:123-36. (PMID: 23666694)
J Mol Diagn. 2022 Feb;24(2):167-176. (PMID: 34775030)
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1637-42. (PMID: 17244711)
J Clin Oncol. 2004 May 1;22(9):1696-705. (PMID: 15117992)
N Engl J Med. 2016 Sep 8;375(10):944-53. (PMID: 27602666)
Bone Marrow Transplant. 2015 Feb;50(2):259-65. (PMID: 25387089)
معلومات مُعتمدة: R41 CA232805 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20230719 Date Completed: 20231023 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC10582300
DOI: 10.1182/bloodadvances.2023010332
PMID: 37467017
قاعدة البيانات: MEDLINE
الوصف
تدمد:2473-9537
DOI:10.1182/bloodadvances.2023010332